IMJUDO is a Intravenous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Astrazeneca Pharmaceuticals Lp. The primary component is Tremelimumab.
Product ID | 0310-4505_6690679c-be2f-4588-a2e4-89fff74dd6be |
NDC | 0310-4505 |
Product Type | Human Prescription Drug |
Proprietary Name | IMJUDO |
Generic Name | Tremelimumab |
Dosage Form | Injection, Solution |
Route of Administration | INTRAVENOUS |
Marketing Start Date | 2022-10-21 |
Marketing Category | BLA / |
Application Number | BLA761289 |
Labeler Name | AstraZeneca Pharmaceuticals LP |
Substance Name | TREMELIMUMAB |
Active Ingredient Strength | 25 mg/1.25mL |
NDC Exclude Flag | N |
Listing Certified Through | 2023-12-31 |
Marketing Start Date | 2022-10-21 |
NDC Exclude Flag | N |
Sample Package? | N |
NDC | Brand Name | Generic Name |
---|---|---|
0310-4505 | IMJUDO | tremelimumab |
0310-4535 | IMJUDO | tremelimumab |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
![]() IMJUDO 90769621 not registered Live/Pending |
AstraZeneca AB 2021-06-11 |
![]() IMJUDO 86484935 5131050 Live/Registered |
AstraZeneca AB 2014-12-18 |